Pfizer Inc has unveiled its financial results for the third quarter of 2025, revealing a mixed performance characterized by a decline in revenues but strong earnings per share. Based on the data provided in the document, the pharmaceutical giant continues to navigate the post-pandemic landscape while focusing on its non-COVID product lines.
Quarterly Revenue Report
The company reported total revenues of $16.7 billion for the quarter, reflecting a 6% decrease compared to the same period last year. This decline is largely attributed to a significant drop in revenues from COVID-19 related products, which have seen reduced demand as the pandemic situation evolves.
Non-COVID Portfolio Performance
Despite the overall revenue dip, Pfizer's non-COVID portfolio demonstrated resilience, achieving a 4% operational revenue growth. This indicates a successful diversification strategy as the company shifts its focus away from pandemic-related products.
Earnings Overview
In terms of earnings, Pfizer reported a diluted earnings per share (EPS) of $0.62, which fell slightly short of market expectations. However, the adjusted diluted EPS came in at $0.87, surpassing forecasts and highlighting the effectiveness of the company's cost management initiatives.
Future Guidance and Cost Savings
Looking forward, Pfizer has raised its full-year EPS guidance to a range of:
- $3.00
- $3.15
Additionally, the company is targeting:
- $7.2 billion in cost savings by 2027
signaling its commitment to maintaining financial health amid changing market conditions.
Eaton Corporation has reported record earnings and sales for Q3 2025, showcasing a strong performance that contrasts with Pfizer's mixed results. For more details, see the full report here.
